Stock comparison
BrainsWay
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BWAY
BrainsWay
Market cap
$592.27M
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BWAY | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 66C | RPRX |
| Benjamin Graham | 70D | 84A | RPRX |
| Philip Fisher | 57C | 65C | RPRX |
| Peter Lynch | 52C | 60C | RPRX |
| Joel Greenblatt | 46D | 40D | BWAY |
| Charlie Munger | 41D | 68D | RPRX |
| Terry Smith | 52D | 58D | RPRX |
Side-by-side metrics
| Metric | BWAY | RPRX |
|---|---|---|
| Market cap | $592.27M | $23.44B |
| P/E (TTM) | 75.0x | 27.6x |
| EV/EBIT | 123.9x | 19.9x |
| ROIC (TTM) | 5.05% | 8.43% |
| Gross margin | 75.42% | 99.95% |
| Net margin | 13.5% | 33.91% |
| Revenue CAGR 5y | 15.42% | 0.96% |
| EPS CAGR 5y | - | 11.83% |
| Debt / Equity | 0.1x | 1.3x |
| Dividend yield | 0.0% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BWAY leads on
- Revenue CAGR 5y15.42%vs 0.96%+94%
- Debt / Equity0.1xvs 1.3x+93%
RPRX leads on
- Dividend yield1.72%vs 0.0%+100%
- Market cap$23.44Bvs $592.27M+97%
- EV/EBIT19.9xvs 123.9x+84%
- P/E (TTM)27.6xvs 75.0x+63%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.